secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-05-21T23:59:59+00:00
Accession:  0001641172-25-011936
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 5.02, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharmaceuticals appoints Alan Weichselbaum as CFO; prior CFO Michelle Yanez resigns
--------------------------------------------------------------------------------

- CFO Michelle Yanez resigned effective May 16, 2025; mutual separation not based on any disagreement.
- Alan Weichselbaum appointed CFO effective May 15, 2025; also CFO of Telomir Pharma and CEO of The Wexus Group.
- Employment agreement: $60,000 annual salary (part-time, 20 hrs/week), 75,000 stock options vesting over 12 months.
- Weichselbaum brings over 30 years of corporate finance experience; previously at Philip Morris and Price Waterhouse.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225011936/0001641172-25-011936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225011936/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-011936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer